Lenacapavir, an injection, has been approved by the FDA for multi-drug resistant HIV.
HIV is not curable yet, but it can be treated successfully throughout someone's lifespan.
Because of its novelty, the drug has a high chance of success since people have not been exposed to it before. It tackles one of the biggest issues when it comes to medication for treatment of HIV:"We define [HIV multi-drug resistance] by people having resistance to two or more drugs in at least three of the four main classes of drugs, and who have fewer than two effective drugs left" to be used as treatment within each of the different classes, Ogbuagu explained.
First, they measured how lenacapavir worked on its own to decrease the virus in the bodies of the people who participated in the trial. Ogbuagu added that"for a group of patients with HIV who have very limited treatment options, due to drug resistance, or intolerance, or safety concerns," the drug managed to suppress the virus in over 80% of individuals."That's incredible," he said.were done with a relatively small group of people since only 8% or less of all the HIV patient population has multi-drug resistance and met that definition in the study, said Ogbuagu.
Data at the end of the first year of their trial showed that receiving the injection helped people strengthen their immune system. Ogbuagu expects this will likely to translate to better protection against possible opportunistic infections like salmonella and tuberculosis, and also to lower the associated risk of death.In essence, lenacapavir tackles the capsid, a conical structure that harbors the RNA of HIV and other proteins that HIV uses to enter and replicate in human cells.
It is also a very potent medication so"a little goes a long way," said Ogbuagu. Patients would only need a lenacapavir injection every 26 weeks, which is approximately every six months.
Danmark Seneste Nyt, Danmark Overskrifter
Similar News:Du kan også læse nyheder, der ligner denne, som vi har indsamlet fra andre nyhedskilder.
More eyedrops contaminated with bacteria are recalled by FDADr Berne's Whole Health Products is issuing a voluntary recall of several eye products because bacteria and fungi were detected, according to the US FDA.
Læs mere »
Study finds potential HIV cure using existing cancer drugAn existing blood cancer drug has shown promise in killing 'silent' HIV cells and delaying reinfections – a significant pre-clinical discovery that could lead to a future cure for the disease.
Læs mere »
'Motherhood is hard': Young, HIV-positive moms in South Africa open up about regret and angerFor any woman, pregnancy and giving birth are major life-changing experiences. Becoming a mother brings with it a range of emotions and, in many African cultures, positive emotions are centered when talking about motherhood.
Læs mere »
Dectin-1 stimulation promotes distinct inflammatory signature in HIV and aging: StudyA new research paper was published on the cover of Aging, titled 'Dectin-1 stimulation promotes a distinct inflammatory signature in the setting of HIV-infection and aging.'
Læs mere »
New gene therapy offers hope for beta thalassemia patientsUCSF Benioff Children's Hospital Oakland provides new therapy to first patient since FDA approval.
Læs mere »
Cancer drug shows promise in killing 'silent' HIV cells and delaying the virus from re-emerging in miceAn existing blood cancer drug has shown promise in killing 'silent' HIV cells in animal models and human cells from people living with HIV—a significant pre-clinical discovery that could lead to a cure for the disease.
Læs mere »